Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

710 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
2014 Update of the drug resistance mutations in HIV-1.
Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, Shafer RW, Richman DD. Wensing AM, et al. Among authors: paredes r. Top Antivir Med. 2014 Jun-Jul;22(3):642-50. Top Antivir Med. 2014. PMID: 25101529 Free PMC article.
Clinical management of HIV-1 resistance.
Paredes R, Clotet B. Paredes R, et al. Antiviral Res. 2010 Jan;85(1):245-65. doi: 10.1016/j.antiviral.2009.09.015. Epub 2009 Oct 4. Antiviral Res. 2010. PMID: 19808056 Review.
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.
Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G; EuroCoord-CHAIN study group. Wittkop L, et al. Among authors: paredes r. Lancet Infect Dis. 2011 May;11(5):363-71. doi: 10.1016/S1473-3099(11)70032-9. Epub 2011 Feb 25. Lancet Infect Dis. 2011. PMID: 21354861 Clinical Trial.
Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.
Gupta S, Vingerhoets J, Fransen S, Tambuyzer L, Azijn H, Frantzell A, Paredes R, Coakley E, Nijs S, Clotet B, Petropoulos CJ, Schapiro J, Huang W, Picchio G. Gupta S, et al. Among authors: paredes r. Antimicrob Agents Chemother. 2011 Jun;55(6):2872-9. doi: 10.1128/AAC.01695-10. Epub 2011 Apr 4. Antimicrob Agents Chemother. 2011. PMID: 21464253 Free PMC article.
Risk of triple-class virological failure in children with HIV: a retrospective cohort study.
Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE); Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A. Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), et al. Lancet. 2011 May 7;377(9777):1580-7. doi: 10.1016/S0140-6736(11)60208-0. Epub 2011 Apr 20. Lancet. 2011. PMID: 21511330 Free PMC article.
710 results